



ventricular hypertrophy on routine electrocardiogram. Some 
peculiarities may be evident on their electrocardiogram (ECG) 
such as repolarisation abnormalities (giant inverted T waves), 
Q waves, left ventricular hypertrophy, left axis deviation, left 
and right atrial abnormalities.(1,9) 
The most sensitive diagnostic tool is echocardiographic with 
proven utility of all three modes.(10,11) The 2-dimensional mode 
is particularly useful in characterising the extent and distribution 
of hypertrophy. The use of M-mode is limited by the need 
for accurate alignment of structures but, when these provisos 
have been met, its high temporal resolution improves the repro-
ducibility of caliper measurements.(10)  Prevalence has been put at 
0.02-0.2% in the general population.(12,13)
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INTRODUCTION                                                               
Hypertrophic cardiomyopathy (HCM) is a primary heart muscle 
disease that is often transmitted as an autosomal dominant 
trait.(1,2) It is characterised by inappropriate myocardial hyper-
trophy of a non-dilated ventricle.(3) This often predominantly 
involves the interventricular septum but other segments of the 
ventricular wall could be affected.(3) 
The disease is characterised by heterogeneity in symptomatology, 
course, phenotypic expression and mutations.(4,5,6,7)  Investigators 
have discovered multiple causative mutations in at least 10 different 
sarcomeric proteins including β-myosin heavy chain, cardiac myosin 
binding protein, cardiac toponin T, α-tropomyosin, essential and 
regulatory light chains and cardiac actin.(6)  The expression of the 
disease could begin in-utero but more commonly becomes mani-
fest in early adolescence to adulthood.(2) 
Common symptoms in HCM include angina, palpitations, syncope 
and exertional dyspnoea.(1,4)  It is a common cause of sudden death 
in young people and accounts for about 36% of sudden death in 
competitive athletes.(8) However, a number of patients are 
asymptomatic and are identifi ed on routine echocardiographic 
examination or during evaluation for a systolic murmur or left 
AIMS: To evaluate the prevalence of hypertrophic cardio-
myopathy (HCM) and its characteristics (clinical, electro-
cardiographic and echocardiographic) in a hospital popula-
tion presenting for echocardiography at the Lagos University 
Teaching Hospital (LUTH).
MATERIALS AND METHOD:  The echocardiographic records 
of patients over a two year period (1998-2000) were reviewed. 
Patients with a diagnosis of HCM were re-evaluated and 
included if they had a hypertrophied non-dilated left ventricle 
with maximal interventricular septum thickness ≥ 15mm and 
interventricular/posterior wall ratio >1.3 in the absence of 
any known cause of hypertrophy.
RESULT: Fourteen (2%) of the 712 patients examined had 
hypertrophic cardiomyopathy with a male preponderance 
(M/F 3.7:1) and mean age of 43.14±15.00yrs. The commonest 
symptoms were chest pain and palpitations in about 50% of 
the subjects. Giant T wave inversion was present on the 
electrocardiogram of 42.9% of the subjects. The mean inter-
ventricular septum was 23.25±7.86mm (range 16 - 36mm) 
and the mean posterior wall thickness was 13.66±7.86mm 
(range 8.3 – 20mm). 
CONCLUSION: Hypertrophic cardiomyopathy occurs in 
about 2% of our population referred for echocardiographic 
examination. Hypertrophic cardiomyopathy should be 
considered in young males presenting with chest pain in 



















There is paucity of data on the prevalence and disease characteris-
tics in Sub-Saharan Africa. This study therefore evaluated the 
prevalence of this disease entity and its characteristics in a 
hospital population presenting at the cardiovascular laboratory 
of the Lagos University Teaching Hospital (LUTH), Nigeria, for 
echocardiography.
METHODS                                                                              
Patient selection
The echocardiographic records of patients presenting at the 
LUTH echo laboratory over a two years period (1998 – 2000) 
were reviewed. Patients’ symptoms and fi ndings on physical 
examination were retrieved from their case fi les. The ECG 
tracings recorded at the time of echo were evaluated inde-
pendently by three cardiologists. ECG features evaluated were 
presence of giant T wave inversion,(14) signifi cant Q waves, QRS 
frontal axis, left ventricular hypertrophy and presence of 
arrhythmias.
The patients who met the inclusion criteria were re-evaluated 
clinically and with echocardiography.
Patients were included in the study if they had asymmetric 
interventricular septal hypertrophy of at least 15mm and if the 
ratio of the interventricular thickness to the posterior wall thick-
ness was equal to or greater than 1.3. or hypertrophy of any 
walls not secondary to loading ventricular abnormalities.(1,5) This is 
in the setting of a non-dilated left ventricle.  An optional inclusion 
criterion was the presence of systolic anterior motion of the 
mitral valve.
Patients with medical conditions likely to cause hypertrophy were 
excluded from the study e.g. aortic stenosis and hypertension.
Echocardiography
Two-dimensional echocardiography:  A Siemens Sonoline S-1450 
real time, phased array ultrasonic scanner with hand-held 3.5 
transducer was used to perform the 2-D echocardiographic 
studies.  Images were analysed online.  Two-dimensional examina-
tions included imaging a number of cross-sectional planes through 
the heart.  Parasternal long axis and short axis views and apical 
four and two chamber views of the heart were obtained with 
standard transducer positions.(15) Echocardiographic studies were 
done with patients in the left lateral position.
M-mode echocardiography: M-mode echocardiograms were 
derived from the 2-D images under direct anatomic visualisation. 
Cardiac dimensions were measured from M-mode echocardio-
grams according to the recommendations of the American Society 
of Echocardiography using the leading edge to leading edge 
methodology.(16)
Doppler evaluation was not performed on the subjects.
Data analysis
The data generated was analysed using the SPSS version 10 
package. Continuous variables are presented as means and 
standard deviation while proportions are presented as per-
centages. Analysis of variance was used in the comparison of 
data from this study and data from other racial groups. Signifi -
cance was said to have been achieved if the p was less than or 
equal to 0.05.
RESULTS                                                                               
During the 2-year period (April 1998 – April 2000) 712 echo-
cardiographic examinations were performed in our laboratory. 
These were patients referred for various reasons ranging from 
comprehensive medical examination to congestive cardiac failure. 
Fourteen(14) of these satisfi ed the diagnostic criteria for hyper-
trophic cardiomyopathy, giving a case prevalence of 2% within 
the clinic setting.  
There were 11 males and 3 females giving a M:F = 3.7:1. The 
mean age of the subjects with HCM was 43.14±15.00yrs. The 
mean systolic and diastolic blood pressures were normal, 
120.45±11.28mmHg and 78.18±8.74mmHg respectively and 
non of the subjects was hypertensive.  
The commonest presentations in our patients were either chest 
pain 50% (7) and palpitations 50% (7). The chest pain was either 
typical angina or atypical chest pain.  Dyspnoea on exertion 
(DOE) was present in 42.9% (6) of the subjects.  These were 
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mainly in NYHA Class II while only 1 person was in NYHA Class III. 
Syncope had been experienced by 28.3% (4) of the subjects. 
However 42.9% of the subjects were asymptomatic (Table I). 
Ejection systolic murmur in the lower left sternal border was 
found in 5 (35%) of the subjects. About half of these also had 
an apical regurgitant systolic murmur while another patient had an 
ejection systolic murmur in the pulmonary area.  Only 1 patient had 
an apical regurgitant murmur alone.  
The results of the electrocardiographic parameters evaluated 
are shown in Tables 2 and 3.  Three subjects had arrhythmias on 
their resting ECG, one had premature ventricular complexes and 
the other two were in atrial fi brillation.  One of the subjects with 
atrial fi brillation had signifi cant QS waves in the anteroseptal 
leads.  Giant T wave inversion was seen in 42.9% (6) of the subjects, 
Figure 1.  This occurred mainly in the precordial leads especially 
septal and anterolateral leads.  The majority of the patients with 
giant-T wave inversion had DOE, 83.33% (5) and lower sternal 
border murmur 83.33% (5). The mean precordial left ventricular 
voltage was 45.50±13.00mm and 71.42% of the subjects had 
ECG left ventricular hypertrophy using the Sokolow and Lyon’s 
criteria.(17)
The subjects had a mean interventricular septum thickness of 
23.25±7.86mm (range 16-36mm) while the mean posterior wall 
HYPERTROPHIC CARDIOMYOPATHY
TABLE 1:   Clinical features of the subjects with hypertrophic 
cardiomyopathy
DOE = dyspnoea on exertion. LSB = lower sternal border. PSM =pan systolic murmur. 
PUL ESM = ejection systolic murmur in the pulmonary area.
Features  Number (n=14)  Percentage
Symptoms  
Asymptomatic  6  42.9
Chest pain  7  50.0
Palpitation  7  50.0
DOE  6  42.9
Syncope  4  28.3
Signs  
Murmurs  7  50.0
LSB ONLY  3  21.4
LSB + APEX  2  14.3
Apical PSM  1  7.1
PUL ESM  1  7.1
TABLE 2:   Selected electrocardiographic features of the subjects with 
hypertrophic cardiomyopathy
Giant T wave inversion = inverted T waves >/=10mm in depth. LAD = left axis deviation.
LVH = left ventricular hypertrophy. PVC = premature. RAD = right axis deviation.
Features  Number (n=14)  Percentage
Axis  
LAD  2  14.3
RAD  3  21.4
Normal axis  9  64.3
Rhythm  
Sinus  11  78.6
Arrhythmias  3  21.4
- Atrial fi brillation  2  14.3
- PVC  1  7.1
QS waves  1  7.1
Giant T wave inversion  6  42.9
LVH  9  64.3
  
FIGURE 1: ECG of one of the subjects showing giant T wave 
inversion in leads V3/V4 plus widespread T wave inversion, right 



















thickness was 13.66±7.86mm (range 8.3-20mm). The mean left 
ventricular dimension in diastole was 41.7±5.70mm while the mean 
systolic left ventricular dimension was 26.77±8.67mm. Systolic 
anterior motion of the mitral valve (SAM) was evident in 2 subjects 
(Table 3).
DISCUSSION                                                                    
Hypertophic cardiomyopathy remains a complex disease with 
variability in prevalence, clinical features and morphological 
abnormalities.(4,5,7,18) This variability has been attributed to the 
disease itself and population bias in the published studies i.e. 
general population versus patients referred to hospitals and 
clinics.(4,19)
This study demonstrated a high prevalence at our centre, 2%.   This 
is much higher than most prevalence reports by other workers 
who reported prevalences of 0.5%(20) for hospital-based echo-
cardiographic studies. Population prevalence fi gure has been 
reported as 0.2%.(12,13) George et al. in 1981,(21) reported 4 cases 
of hypertrophic cardiomyopathy at our centre seen over a 5-year 
period. Maro et al. reported a prevalence of 0.19% over a 
4-year period at a hospital echocardiographic referral centre in 
Tanzania.(22) The very high prevalence may be related to the 
highly selected group we studied.  Most of these patients were 
referred for echocardiography on the grounds of clinical and 
electrocardiographic suspicion of heart disease. The wide geo-
graphical area served by the Lagos University Teaching Hospital 
may have affected our prevalence.  Also the limited accessibility 
to echocardiography in Nigeria will lead to concentration of 
cases in a few centers such as ours and this could have affected 
our case prevalence. On the other hand, there is a possibility 
that hypertrophic cardiomyopathy is more prevalent in people 
of African descent.  That remains to be established by larger 
population studies. Amoah et al. in their review of the aetiology of 
heart failure at the Ghana National Cardiac reference centre 
reported that HCM was seen in 9 patients which accounted 
for 9.4% of the cardiomyopathies. This will translate into 1.15% 
of the study population of 572.(23)  Also Abegaz in his review of 
1 240 abnormal echocardiograms at the Armed Forces General 
Hospital in Ethiopia from 1984 to 1988 identifi ed 53 cases of 
HCM in that cohort.(24) Lewis et al. in his study of South African 
Blacks discovered 7 cases over a 14-month period.(25) It is 
important to note that in the study by Maron et al.(12) using 
subject in the CARDIA study, prevalence of HCM in blacks was 
two-folds that of whites (0.24:0.0%, 5 blacks and 2 whites).  In 
addition the studies by Maron et al. on sudden death in competi-
tive athletes showed a signifi cantly higher proportion of deaths 
from HCM in African Americans than in their Caucasian counter-
parts (48% vs. 26% p=0.01)(8) and (55% vs. 42% p=0.002).(26) 
The M: F ratio found in our study group was 3.7:1.  This is in keeping 
with the male preponderance reported by other workers.(1,12,13) 
The four cases reported by George et al. were all males.  However 
Maron et al. in a study of outpatients referred for echocardio-
graphy had 3 females in the 4 cases of HCM picked up.(20) 
Almost half of the subjects were asymptomatic. Eighteen of 
Braunwald’s original 64 patients were actually asymptomatic at 
the time of diagnosis.(1) In the population study by Maron et al.,(2) 
50% of the subjects were asymptomatic. Six of the 7 patients 
found in the CARDIA study were also asymptomatic.(12) Most 
of the asymptomatic subjects in our study were picked up 
either from further work up for X-ray cardiomegaly or very tall 
precordial voltages and giant T wave inversion on routine 
electrocardiogram.  However a few others were diagnosed during 
routine echocardiography done for comprehensive medical 
evaluation. 
TABLE 3:   Comparison of electrocardiographic and some echocardio-
graphic features in the present study with studies in 
Caucasians and Japanese
IVS = interventricular septum. LVDD = left ventricular internal diameter in diastole. LVH = left 
ventricular hypertrophy. LVOT = left ventricular outfl ow tract. SAM = systolic anterior motion.
Feature  Present  Maron Hada Savage P value
 study et al.(12) et al.(13) et al.(9)
Number of patients 14 7 22 134 –
Abnormal ECG (%) 12(85.7) 5(71.4) 22(100) 123(91.8) –
Arrhythmias (%) 3(21.4) – – – –
Left axis deviation 2(14.3) – – 50/132(37.8) 0.14
Right axis deviation 3(21.4) – – – –
Q waves 1(7.2) 1(14.3) 2(9) 44(32.8) 0.026
LVH 9(64.3) 2(28.6) 15(68.2) 65/102(63.7) 0.28
ST-depression  11(78.6) 5(71.4) 18(81) 108(80.6) 0.93
T wave inversion 
Giant T wave  6(42.9) 1(14.3) 4(18) – 0.19
inversion
LVOT obstruction/  2(14.3) 4(57.1) 3(9.1) – 0.01
SAM (%)
IVS (mm) 23.25±7.86 17.14±2.03 16.86±3.56 – 0.002
Posterior wall (mm) 13.66±7.86 10.86±1.77 11.50±1.47 – 0.30
LVDD (mm) 41.71±5.70 47±8.9 – – 0.04
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The commonest symptom seen in this study was chest pain.  This 
was sometimes atypical in nature. Chest pain as a common 
presenting feature in HCM has been documented by other 
workers,(1,25,27) even in the absence of obstructive coronary 
artery disease.  This is thought to be due to regional myocardial 
ischaemia which occurs as a result of increased oxygen demand, 
reduced coronary vasodilator response, increased fi lling pressures 
and abnormalities in fi lling pressures.(4,27) In the present study 
there was no relationship between chest pain and T wave inver-
sion.  The two other very common symptoms encountered in this 
study were palpitations and dyspnoea on exertion. This is similar 
to fi ndings in other studies.(1,28)
Giant T wave inversion was seen in about 40% of the subjects in 
this study. These were not patients with the apical variety of 
asymmetric hypertrophy described by the Japanese group.(14) 
However the mean depth of the giant T wave inversion was not 
as much as that reported in the Japanese study and it occurred 
mainly in the septal to anterolateral leads, (-1.2 vs -1.63 mV).(14) 
Giant T wave inversion especially in the precordial leads was seen 
in most of the subjects who had left sternal border systolic 
murmurs and dyspnoea on exertion. The reasons for these 
observations are not apparent from the present study. The use 
of invasive haemodynamic may be useful to further evaluate 
these observations. Earlier studies by Braunwald(1) however, did 
not show any correlation between symptoms of dyspnoea, 
chest pain, syncope, dizziness and edema with outfl ow gradient 
or the left ventricular end diastolic pressures. 
The commonest arrhythmia noted on the resting ECG was atrial 
fi brillation in 2 of the subjects.  Atrial fi brillation prevalence in this 
study is consistent with earlier reports.(29,30) Olivetti et al.(31) 
documented a turning point in the course of the disease in a 
community study with onset of atrial fi brillation as regards HCM 
related mortality, symptomatic deterioration and risk of stroke. 
The impact of this arrhythmia on the prognosis of HCM has 
been controversial. While earlier authors have reported acute 
decompensation with onset of this arrhythmia,(30) others did 
not(29) and this was attributed to the type of cohort, community 
versus hospital referral cohort. The 2 patients in our series 
developed embolic stoke, 1 despite anticoagulation and the other 
was not adherent to anticoagulants.  A third patient died suddenly 
before getting to the hospital without documentation of his exit 
rhythm. This might not be the representative pattern of arrhyth-
mias in our environment as continuous ECG monitoring was not 
done on the subjects.
The mean interventricular septum measurement was comparable 
to that of other reported studies.(9,28) As expected the subjects 
had marked thickness of their interventricular septum. The 
posterior wall thickness was also more than the accepted  values 
in a normal population. These fi ndings in the setting of small 
ventricular cavity size is in keeping with usual fi ndings in HCM.
The comparison with Caucasian and Japanese racial groups 
revealed similar mean ages at presentation and male preponder-
ance in the disease manifestation. The present study pooled 
subjects mainly from individuals already suspected of having 
cardiac disease while the study by Maron and Hada was on 
apparently healthy individuals from the general population. The 
lower prevalence of pathological Q waves in the present study 
may have been as a result of the low prevalence of ischaemic 
heart disease in our environment. Selection bias and small 
numbers must also be taken into consideration. However a higher 
proportion of our subjects had giant T wave inversion than 
subjects in the Caucasian and Japanese racial groups. These 
patients did not have the defi nite apical variety of HCM 
described by the Japanese. It is possible that giant T wave inver-
sion is a feature in extensive disease and not necessarily the apical 
variety. It is interesting to note however that the subjects in this 
study had higher mean interventricular septal thickness when 
compared with Caucasian and Japanese racial groups. This may 
refl ect a higher burden of disease in this environment. However 
the effect of selection bias and the small numbers in this study 
cannot be ignored.
CONCLUSION                                                                  
We conclude that hypertrophic cardiomyopathy does exist in this 
part of the world and the disease burden may be greater in our 
patients. Community-based studies will be needed to confi rm 
this. Common symptoms encountered include chest pain, palpi-
tations and dyspnoea on exertion.
Therefore, HCM should be considered in unexplained chest pain 
in young persons in Nigeria. Giant T wave inversion may be an 
important indicator of hypertrophic cardiomyopathy and not 
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